MedTrace Logo

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

NCT05238337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-08-30

No results posted yet for this study

Summary

This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.

Conditions

  • Absorption, Metabolism and Excretion in Healthy Volunteers

Interventions

DRUG

[14C]-PBI-200

\[14C\]-radio-labeled-PBI-200

Sponsors & Collaborators

  • Pyramid Biosciences

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Pyramid Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2022-03-24
Completion
2022-03-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238337 on ClinicalTrials.gov